Tag: CMC

Addressing Missing QbD Elements in IND/NDA Filings to Avoid Late-Stage Reformulation The pharmaceutical development landscape has increasingly emphasized Quality by Design (QbD) to ensure more predictable outcomes from IND/NDA filings.…

Addressing Missing QbD Elements in IND/NDA Filings to Prevent Late-Stage Reformulations In today’s rapidly evolving pharmaceutical landscape, ensuring a robust Quality by Design (QbD) framework during the Investigational New Drug…

Managing Bioavailability Risks During Early Development: A Comprehensive Playbook Bioavailability risk flagged during early development can significantly impact project timelines and regulatory approval pathways. Understanding the early indicators and having…

Strategies to Address Scalability Issues in Prototype During IND/NDA Filings In the pharmaceutical industry, transitioning a prototype formulation to a scalable process is imperative, especially during Investigational New Drug (IND)…

Addressing Late-Identified Excipient Incompatibility During Tech Transfer: A Comprehensive Playbook In the pharmaceutical industry, the successful transfer of a process from development to manufacturing is critical for ensuring product quality…

CMCs and Bioavailability Risks: A Comprehensive Playbook for Regulatory Optimization In the highly regulated environment of pharmaceutical drug development, bioavailability risks flagged during regulatory review can present significant challenges. These…

Managing Bioavailability Risks Identified During Tech Transfer: A Comprehensive Playbook Bioavailability risks often surface during the tech transfer phase of drug development, posing challenges for formulation and process consistency. Understanding…

Addressing Missing QbD Elements in Scale-Up Preparation: A Regulatory Compliance Playbook The pharmaceutical industry faces significant challenges during the scale-up phase of formulation development. As processes evolve from early-stage trials…

Addressing Unexplained Dissolution Variability During Early Development to Avoid Late-Stage Reformulation Dissolution variability during early development phases can pose significant challenges in formulation development. It can lead to delayed timelines,…

Strategies to Address Unexplained Dissolution Variability in Early Development Stages In the realm of pharmaceutical development, unexplained dissolution variability can pose significant challenges during formulation development. Not only does it…

Managing Bioavailability Risks During Technology Transfer: An Actionable Playbook In the highly regulated world of pharmaceutical manufacturing, one significant concern that can surface during the technology transfer phase is the…

Strategies to Address Stability Failures During Tech Transfer in Formulation Development Formulation development is a critical phase in drug manufacturing, particularly during tech transfer when production processes scale up. Failing…